Bipartisan Health Care Act

Redesignates the second subsection designated as subsection (l) as subsection (m), and makes textual amendments within the redesignated subsection (m)(1), including inserting references to 'podiatric medicine' and minor wording/punctuation changes in specified subclauses and clauses.

Adds new section 9826 ('Oversight of entities that provide pharmacy benefit management services') to subchapter B of the Internal Revenue Code, establishing contract and reporting requirements for entities providing PBM services to group health plans and defining related terms (reporting frequency, required data elements, limited public disclosure, rulemaking deadlines)

Amends 26 U.S.C. §9831 (general exceptions) to insert an exception for certain group health plans as specified by the new provisions related to PBM reporting and treatment of group health plans in this title

Adds a new subsection (g) to 26 U.S.C. §4980D clarifying that, for purposes of the new §9826 requirements that apply with respect to entities providing PBM services on behalf of group health plans, references to a group health plan (and the employer reference in subsection (e)(1)) shall be treated as including such entities providing PBM services

Amends 29 U.S.C. §1108 (exemptions from prohibited transactions under ERISA) including redesignation of subclauses and insertion of new clauses/subparagraphs that (among other changes) make certain PBM contract arrangements reasonable only if PBM entities meet specified transparency and remittance conditions, require remittance timing and auditability of rebate/fee records, and clarify covered service providers and fiduciary monitoring duties

Amends 21 U.S.C. §505(j)(3) (the abbreviated new drug application provision) by adding a new subparagraph (H) that authorizes the Secretary to inform or determine whether a proposed generic drug is qualitatively and quantitatively the same as a listed drug (including disclosure of ingredients causing differences), and sets related procedural protections and limitations on disclosure; companion guidance timelines are required of the Secretary of Health and Human Services

Amends 35 U.S.C. §271(e) to extend the act of infringement, with respect to certain submissions described in paragraph (2)(C)(ii), to any patent that claims the biological product, a method of using the biological product, or a method or product used to manufacture the biological product

Adds an additional subparagraph (J) providing $4,600,000,000 for fiscal year 2026 to the list of amounts in section 10503(b)(1) of the Affordable Care Act (community health centers)

Adds an additional subparagraph (J) providing $350,000,000 for fiscal year 2026 to the list of amounts in section 10503(b)(2) of the Affordable Care Act (National Health Service Corps)

Adds multiple subparagraphs (F)–(J) specifying funding amounts for teaching health centers for specified periods/fiscal years (Jan 1–Sep 30, 2025 and FY2026–FY2029)